The MarketWatch News Department was not involved in the creation of this content.-- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authoriz ...
Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...
BOSTON — Health care professionals should use a broad range of tools to diagnose diabetic peripheral neuropathy, and ...
A Michigan State University researcher has found that diet and food insecurity may contribute to the development of ...
Early signs of vitamin B12 deficiency often manifest in the toes, with tingling, numbness, or a burning sensation indicating ...
One Michigan State University researcher discovered our diets may play a key role as to why some people develop this ...
Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-1402 development is progressing ...
Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S. neurologists across five key neurological ...
One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of ...
The world marks World Diabetes Day on November 14 each year, with the aim of raising global awareness to combat the disease ...
Researchers have found that the severity of diabetic retinopathy (DR) and the presence of diabetic macular edema (DME) are ...
12don MSN
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback